In the MATCH clinical trial, 26 patients received macrophage therapy while 24 had standard care.
The findings highlight the macrophage therapy’s potential as another option for end-stage liver disease. Credit: DW2630 / Shutterstock.com.
Scientists at the University of Edinburgh have developed a new cell therapy aiming to provide a potential alternative to liver transplants for patients with advanced liver disease.
The therapy uses patients’ immune cells, developed into mature macrophages, which are then re-infused to break down scar tissue and promote the growth of healthy liver cells. Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
